Andrx Comments on FDA Approval of its Generic OTC Claritin-D 12.

Business Editors/Health/Medical Writers

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Jan. 29, 2004

Andrx Corporation (Nasdaq:ADRX) today announced that the United States Food and Drug Administration (FDA) has approved the Company's Abbreviated New Drug Application (ANDA) for Loratadine and Pseudoephedrine Sulfate Extended-release Tablets 5 mg/120 mg (12-Hour Formulation), which are bioequivalent to Schering Corporation's Claritin-D(R) 12 Hour Extended-release Tablets (Claritin-D12). Labeled for the relief of symptoms of seasonal allergic rhinitis (hay fever), this product will be marketed as an over-the-counter (OTC) product by Perrigo Company, the nation's largest provider of store brand OTC pharmaceuticals. Perrigo is presently marketing Andrx's bioequivalent OTC versions of Claritin-D(R) 24 and recently began shipment of the Company's OTC Claritin RediTabs(R) product into the trade. The Company does not presently have a launch date for its OTC version of Claritin-D12 as it prioritizing its manufacturing efforts among its various products.

Larry Rosenthal, President of Andrx Pharmaceuticals, said: "We are very pleased that our OTC Claritin RediTabs will soon be on store shelves joining our OTC Claritin D-24 product and that our OTC Claritin-D12 has now been approved."

About Andrx Corporation:

Andrx Corporation develops and commercializes: bioequivalent versions of controlled-release brand name pharmaceuticals, using its proprietary drug delivery technologies; bioequivalent versions of specialty, niche and immediate-release pharmaceutical products, including oral contraceptives; and brand name or proprietary controlled-release formulations of existing immediate-release or controlled-release drugs where it believes the application of Andrx's drug delivery technologies may improve the efficacy or other characteristics of those products. Andrx also has distribution operations, which purchase primarily generic pharmaceuticals manufactured by third parties and sell them primarily to independent pharmacies, pharmacy chains, pharmacy buying groups and, to a lesser extent, physicians' offices.

Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein or which are otherwise made by or on behalf of the Company that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "would," "estimate," or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Investors are cautioned that all forward-looking statements involve risk and uncertainties, including but not limited to: the Company's dependence on a relatively small number of products; licensing revenues; the timing of FDA approvals for the Company's ANDAs; the successful scale-up, timing and commercial success of future product launches, including OTC Claritin D-12; the timing and outcome of litigation; government regulation; competition; and manufacturing results. Andrx Corporation is also subject to other risks detailed herein or detailed from time to time in its filings with the U.S. Securities and Exchange Commission. Andrx disclaims any responsibility to update the statements contained herein.

This release and additional information about Andrx Corporation are also available on the Internet at: http://www.andrx.com.